The FDA listing of Sienna’s first IVD product means the SCD-A7 reagent can be used for clinical diagnostic purposes by pathology labs in the United States. CE marking and IVD registration in Europe and Australia means the same is true for those markets also. Clinical pathology labs in those regions may now purchase SCD-A7 for use as an in vitro diagnostic test for the presence of hTERT, a component of telomerase. This is a significant world-first since never before has a telomerase-based assay been made available to pathology laboratories for use on human clinical specimens
wtf.....im going to keep buying and buying. this will be 20 to 30 baggers
most bio companies get 50 to 100mill market cap for announcing they got a new coffee machine.
SDX Price at posting:
6.1¢ Sentiment: Buy Disclosure: Held